Alder BioPharmaceuticals® to Present at the 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 07h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare Conference
22 nov. 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...
Alder BioPharmaceuticals® Announces Third Quarter 2017 Financial and Operating Results
07 nov. 2017 16h24 HE
|
Alder BioPharmaceuticals, Inc.
– PROMISE 2 pivotal trial completed enrollment and top-line data on track for 1H18 – – Eptinezumab Biologics License Application (BLA) submission on track for 2H18 – – Conference call scheduled for...
Alder BioPharmaceuticals® to Present at 26th Annual Credit Suisse Healthcare Conference
01 nov. 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Third Quarter 2017 Financial and Operating Results
31 oct. 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...
Alder BioPharmaceuticals® to Present Data from Eptinezumab Development Program at 18th Congress of the International Headache Society
07 sept. 2017 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...
Alder BioPharmaceuticals® to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
05 sept. 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics today...
Alder BioPharmaceuticals® Announces Second Quarter 2017 Financial and Operating Results
08 août 2017 16h05 HE
|
Alder BioPharmaceuticals, Inc.
– Positive top-line PROMISE 1 study results further support eptinezumab’s unique clinical profile – – $161.5 million from recent public offering expected to enable continued advancement of...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results
01 août 2017 08h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...
Alder BioPharmaceuticals Announces Closing of Public Offering of Common Stock
18 juil. 2017 11h00 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 18, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate...